7 Best Medical Technology Stocks To Buy According To Analysts

5. Glaukos Corporation (NYSE:GKOS)

Price Target Upside: 27.90%

Glaukos Corporation (NYSE:GKOS) is a medical technology company focused on innovative treatments for eye diseases like glaucoma, corneal disorders, and retinal diseases. The company develops micro-invasive surgical devices and drug delivery systems to improve patient outcomes. Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three years.

Glaukos Corporation (NYSE:GKOS) reported a strong performance in Q4 2024, with net sales reaching $105.5 million, a 28% increase year-over-year. Full-year 2024 sales totaled $383.5 million, up 22% from 2023, and the company expects continued growth with a projected sales range of $475 to $485 million for 2025. The growth was mainly driven by the success of iDose TR, a novel glaucoma therapy, which saw record sales in Q4. This dropless treatment is gaining popularity for its ability to improve patient outcomes.

Glaukos Corporation (NYSE:GKOS) faces potential challenges, such as foreign currency fluctuations, competition in international markets, reimbursement issues, and the expiration of the Hydros royalty, which may affect revenues outside of iDose TR. Despite these hurdles, the company is seen as a leader in the glaucoma market, with promising prospects for further growth in the ophthalmology sector.